Pioneering launch highlights India’s emergence as a global innovation hub in structural heart care.

Meril Life Sciences, one of India’s foremost global med-tech companies, has made a breakthrough in the field of structural heart therapies with the official launch of MyClip — the nation’s first Transcatheter Edge-to-Edge Repair (TEER) system for managing severe Mitral Regurgitation (MR). The innovation was unveiled at the Structural Heart Innovation event hosted at Meril Academy in Vapi, Gujarat, from June 13 to 15, drawing participation from over 150 leading Indian interventional cardiologists and several globally renowned cardiac experts.

The MyClip TEER system is designed as a life-saving, minimally invasive solution for patients suffering from symptomatic and severe MR, particularly those deemed high-risk for open-heart surgery due to comorbidities such as hypertension, diabetes, obesity, frailty, or multi-organ dysfunction. This advancement positions India as a serious contender in the global med-tech landscape, with Meril now offering both replacement and repair platforms in transcatheter heart valve therapies — a rare distinction.

The event witnessed the presence of global pioneers in mitral valve intervention, including Prof. Ottavio Alfieri — widely regarded as the father of mitral valve repair — along with Prof. Francesco Maisano and Prof. Agricola, who led expert-led case discussions, workshops, and hands-on sessions focused on TEER technology.

Speaking at the launch, Sanjeev Bhatt, Senior Vice President – Corporate Strategy, Meril Life Sciences, emphasised the growing clinical burden of MR in India. “An estimated 1.5 million Indians suffer from severe mitral regurgitation, of which nearly 1.2 million are linked to post-myocardial infarction complications or heart failure. MyClip represents a critical milestone in making advanced structural heart care more accessible and clinically effective in our country,” he said.

Bhatt also highlighted Meril’s proactive approach in supporting the TEER ecosystem through structured training programs for cardiologists and echocardiographers, as well as its large-scale public education initiative #TreatmentZarooriHai featuring MS Dhoni, aimed at spreading awareness about early intervention in MR cases.

Clinical Significance of MyClip TEER

TEER is fast emerging as a reliable and effective option over conventional guideline-directed medical therapy (GDMT), especially for patients who cannot undergo surgery. The procedure, performed via a catheter-based approach, uses MyClip to precisely close the flaps of the mitral valve, preventing reverse blood flow into the lungs and significantly improving cardiac function.

Minimally invasive by design, the procedure takes about an hour to complete, with patients typically discharged within 3–5 days. Recovery is relatively swift, allowing return to daily, non-strenuous activities shortly after hospital discharge.

The evidence in support of TEER continues to grow. The landmark COAPT Trial, published in the New England Journal of Medicine, showed that patients who underwent TEER had significantly improved outcomes. Over a 24-month follow-up period, heart failure hospitalisations dropped to 35.8% per patient-year, compared to 67.9% in patients receiving medical management alone. Similarly, the mortality rate was reduced from 46.1% in the control group to 29.1% in the device group.

Charting a New Path for Cardiac Care in India

Despite the promising outlook, India currently sees only around 150 TEER procedures performed annually — a modest figure given the scale of disease burden. Notably, a significant proportion of these patients are in the 30–60 age group, underlining the urgent need for early detection and intervention, especially in younger demographics.

By introducing MyClip, Meril is not only addressing this unmet clinical need but is also fostering a scalable and self-reliant ecosystem for TEER adoption in India. The Structural Heart Innovation program further reinforced this commitment by focusing on skill-building, clinical excellence, and sustainable growth through multi-stakeholder collaboration.

MyClip is poised to play a vital role in redefining how structural heart diseases are managed in India, setting a strong precedent for indigenously developed, globally benchmarked cardiovascular technologies.

Also read: Jupiter Hospital Installs India’s First GE Allia IGS 530 Cath Lab, Enhancing Patient Safety & Speeding Recovery

Key Highlights for the Industry

• India’s First TEER System: MyClip positions Meril and India at the forefront of transcatheter mitral repair innovation.
• Focus on High-Risk Patients: Designed for those who cannot undergo open-heart surgery due to age or health complications.
• Global Expert Endorsement: Launch supported by leading global figures in structural heart therapy.
• Clinically Backed Outcomes: Aligns with global clinical trial evidence indicating reduced mortality and hospitalisation.
• Public Engagement: National awareness campaign spearheaded by MS Dhoni to drive early diagnosis and intervention.

This development opens new horizons for cardiology practices, hospital infrastructure, and patient care pathways in India. With MyClip, Meril Life Sciences reinforces its leadership in pioneering cardiovascular solutions rooted in Indian innovation with global impact.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!